『Shot of Digital Health Therapy』のカバーアート

Shot of Digital Health Therapy

Shot of Digital Health Therapy

著者： Eugene Borukhovich and Jim Joyce
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
A Shot of Digital Health Therapy is a meticulously unproduced podcast hosted by health tech founders Eugene Borukhovich and Jim Joyce. Born in the pandemic, therapeutic by design—oh, and comedy is still included. We dive into unscripted conversations with the people shaping employer benefits, digital health moonshots, and the broader healthcare system. From real talk to ridiculous tangents, we spotlight the builders, thinkers, and occasional troublemakers moving the industry forward. We'd love to have you join us.2020-2025 Eugene Borukhovich and Jim Joyce 経済学 衛生・健康的な生活
エピソード
  • Pablos Holman, Founder, Deep Future, on Why One Blood Test Could Predict What Kills You

    Pablos Holman, Founder, Deep Future, on Why One Blood Test Could Predict What Kills You
    2026/09/10
    Pablos Holman - hacker, Blue Origin alum, co-founder of a 6,000-patent invention lab with Bill Gates and Nathan Myhrvold, and now founder of the venture fund Deep Future - joins Jim Joyce and Eugene Borukhovich for a long-format conversation that starts in an Alaska basement and ends in a proteomic blood test that can already predict what kills you. Along the way: why he coined the term "shallow tech" for the last two decades of Silicon Valley, why the invention labs before his kept under-commercializing their own breakthroughs, and his case for why healthcare needs to work like Amazon and Google Maps combined before any of the rest of it matters. 00:00 - Cold Open - Letting Pablos In02:36 - Why This One's Different: The Long-Format Experiment03:21 - Born in Alaska With a Computer Nobody Had Seen10:23 - The Reverse-Engineering Mantra17:06 - What a Hacker Actually Is26:27 - From Dot-Com Bust to Blue Origin30:29 - Inventing 6,000 Patents With Bill Gates and Nathan Myhrvold36:21 - Why Invention Capital Beats Traditional VC43:49 - The Gwynne Shotwell Problem50:31 - The Case for Paying Inventors Like Musicians54:13 - Healthcare's 18 Trillion Dollar Problem59:11 - Alden Scientific: One Blood Test to Predict What Kills You1:03:12 - The Amazon-and-Google-Maps Vision for Healthcare1:06:40 - 3D-Printed Food, Revisited a Decade Later1:12:35 - Holobiome and the Return of Microbiome Science1:15:26 - AI, Hammers, and Who Should Decide What Matters1:20:33 - The Signature Question: Advice to His Younger Self1:29:05 - Where to Find Pablos Guest: Pablos Holman, Founder, Deep Future - LinkedIn - deepfuture.tech Mentioned in this episode: Blue Origin, Intellectual Ventures, Alden Scientific, Holobiome, Gwynne Shotwell (SpaceX), Neal Stephenson. If you enjoyed this episode, subscribe and leave a review - it's the easiest way to help more people find the show.
    続きを読む 一部表示
    1 時間 31 分
  • Liana Douillet Guzman, Folx Health, on Why "Willing to Care" for LGBTQ+ Doctor Search Drops 20K to 600

    Liana Douillet Guzman, Folx Health, on Why "Willing to Care" for LGBTQ+ Doctor Search Drops 20K to 600
    2026/09/03
    Liana Douillet Guzman is the CEO of Folx Health, the LGBTQIA+ healthcare platform she almost didn't take the job to run. In this episode, Liana joins Eugene and co-host Marina Berhovic (in for a traveling Jim Joyce) to walk through why 95% of people who come to Folx say they never had an affirming provider before, why the average clinician graduates with roughly five hours of LGBTQIA+-specific training, and why a routine "find a doctor" search can drop from 20,000 providers to 600 once you filter for who is actually willing to treat this community. Liana also traces her own winding path here, through legal tech, crypto, and online education, and gets candid about where she thinks clinical AI is already failing trans patients, including a real case where an AI system recommended conversion therapy. 00:00 - Cold Open - Marina Steps In as Co-Host01:36 - Liana's Origin Story - Puerto Rico to Connecticut07:01 - Falling Into Marketing by Accident10:56 - Ten Years at Axiom, Then COO at Blockchain11:57 - The Call From Folx - Why a Reluctant CEO Said Yes20:35 - The Pediatrician Form That Changed Everything24:54 - What Folx Health Actually Does27:00 - 95 Percent Had No Affirming Provider Before Folx27:19 - Five Hours - The Entire LGBTQIA Medical Curriculum29:00 - From Cash-Pay to Every National Payer33:34 - The Search That Drops 20,000 Doctors to 60039:00 - Ignorant at Scale - AI's Data Problem for Trans Patients42:54 - Why AI-First Health Companies Race to the Bottom43:45 - When AI Recommended Conversion Therapy45:34 - The Shot Question - Advice to Younger Liana Guest: Liana Douillet Guzman, CEO, Folx Health - LinkedIn - folxhealth.com Mentioned in this episode: Marina Berhovic, Lee Shapiro, Kate Steinle (Folx Chief Clinical Officer), Point of Pride, Blue Shield of California. If you enjoyed this episode, subscribe and leave a review - it's the easiest way to help more people find the show.
    続きを読む 一部表示
    51 分
  • Sean Glynn, Noble on Why an 88% Adoption Rate Proves “Adherence” Was the Wrong Word

    Sean Glynn, Noble on Why an 88% Adoption Rate Proves “Adherence” Was the Wrong Word
    2026/08/20
    Sean Glynn leads patient engagement and evidence programs at Noble, a division of Aptar Pharma. Sean joins Jim Joyce and Eugene to unpack why he thinks medication adherence still isn't solved, and why he'd retire the word "adherence" altogether. His team's SureStart Rx program moved injection training out of doctors' offices and into specialty pharmacy workflows, and the pilot data holds up: 88% patient usage, first doses 3.5 days sooner, and one to two extra doses over six months. Sean also traces the winding path that got him here: organizational behavior grad school, a house-flipping business, pharmacoeconomics at the University of Florida, Health Beacon, and ZS Associates. 00:00 - Cold Open - The Dose Is the Poison02:00 - Meet Sean Glynn - Noble, Aptar, and a Decades-Long Friendship04:00 - Irish Roots and the Family That Reverse-Immigrated Twice09:00 - Delicate Hands to Org Behavior - Finding the Thing13:00 - The Metric Pharma Got Wrong - Commitment Beats Satisfaction18:00 - The Construction Detour, and How Health Beacon Started23:00 - ZS Associates, WHOOP, and the Integrated Evidence Plans26:00 - Dying on the Vine - Why Evidence Plans Get Skipped30:00 - The Noble Pivot - SureStart Rx and the Distribution Problem35:00 - Becoming an Intrapreneur Inside a 9-Billion-Dollar Company38:00 - Why Injections Are Still Genuinely Hard40:00 - The Ozempic Story, Cold Plunges, and Ronaldo's Free Kick44:00 - Killing the Word "Adherence"48:00 - Where Noble Goes Next - AI, Sensors, and Global Expansion50:00 - Closing Question - Advice to His Younger Self Guest: Sean Glynn, Noble / Aptar Pharma - LinkedIn | Noble | Aptar Pharma Mentioned in this episode: Sean McDade and PeopleMetrics, Craig Baker and Jeff Baker (Noble's founders), BioPlus Specialty Pharmacy, WHOOP, ZS Associates, Health Beacon, University of Florida. If you enjoyed this episode, subscribe and leave a review - it's the easiest way to help more people find the show.
    続きを読む 一部表示
    55 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません